Crizotinib (PF-02341066)

Pfizer辉瑞授权 目录号:S1068

Crizotinib (PF-02341066) Chemical Structure

Molecular Weight(MW): 450.34

Crizotinib (PF-02341066) 克唑替尼是一种有效的c-MetALK抑制剂,在细胞试验中IC50分别为11 nM 和 24 nM。

规格 价格 库存 购买数量  
RMB 1812.55 现货
RMB 900.49 现货
RMB 1372.81 现货
RMB 4681.47 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献75篇:

客户使用该产品的13个实验数据:

  • (c) Western blot analyses of p-Akt (Ser473) and p-S6RP (Ser235 and Ser236) in two RCT-E565 transplanted tumors treated with vehicle or PF02341066. Samples were isolated 4 h after the last dose from mice treated with PF02341066 for 3 d. (d) Responses of RCT-E565 transplanted tumors in athymic mice to PF02341066 or vehicle. Data are means ±s.e.m. (each group, n = 6). *P < 0.005, **P < 0.001 (Student,s t test).

    Nat Med 2011 17, 1116-1120. Crizotinib (PF-02341066) purchased from Selleck.

    Ba/F3 cells grown in the presence of IL-3, or Ba/F3 cells expressing native EML4-ALK (clone #2, #10, #101, and #155) and EML4-ALK L1196M (clone #216, #302, #303, and #355), were treated with CH5424802 or PF-02341066 for 48 hr, and then the viable cells were measured by the Cell Titer-Glo Luminescent Cell Viability Assay. IC50 values were determined by plotting the drug concentration versus percentage of cell growth inhibition. Data are shown as mean ±SD (n = 3).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

  • Mice bearing Ba/F3-EML4-ALK (clone #10) and EML4-ALK L1196M (clone #303) were administered vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg) orally once daily for 8 days. Tumor volume for each dose group was measured. Data are shown as mean ± SD (n = 5). Parametric Dunnett’s test: ***p < 0.001; N.S., not significant, versus vehicle treatment at final day. For pharmacodynamic assay, mice bearing Ba/F3-EML4-ALK (clone #10) and -EML4-ALK L1196M (clone #303) were orally administered at single dose of vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg), and the tumors were collected and lysed at 4 hr post-dosing. STAT3 and phosphorylated STAT3 (Tyr 705) were detected by immunoblot analysis using antibodies against each of them (n = 2 per group).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

    (A) Immunoblots of MPM cells treated with the indicated concentrations of crizotinib alone for 24 h with HGF stimulation.

    Sci Rep, 2016, 6:32992. Crizotinib (PF-02341066) purchased from Selleck.

  • Three MET amplified (Hs746t, SNU-5 and MKN45) and two non-amplified cell lines (MKN74 and NUGC-4) were incubated with or without 100nM crizotinib 24 hours, and total protein was extracted using RIPA lysis buffer. Total lysates were then analyzed by immunoblotting using anti-phospho-MET, anti-total-MET, and β-actin antibodies.

    Oncotarget, 2017, 8(31):51675-51687. Crizotinib (PF-02341066) purchased from Selleck.

    Viability of Ba/F3 cells stably expressing DCTN1-ALK or EML4-ALK cDNAs after treatment with crizotinib (C). Ba/F3 cells transduced with lentiviral cDNA or empty vector were subjected to the assay, and the number of cells was counted at 72 hours.

    Oncologist, 2017, 22(2):158-164. Crizotinib (PF-02341066) purchased from Selleck.

  • Combination of EGCG with c-MET inhibitor has enhanced inhibitory effects on the growth of OS cells. MG-63 and U-2OS cells were treated with crizotinib (0.05 mM) and/or EGCG (0.08 g/L) for 48 h, and the effects on cell apoptosis (b) were determined using flow cytometry. *P<0.05 versus the control; #P<0.05 versus crizotinib-treated groups or EGCG-treated groups

    Tumour Biol, 2016, 37(4):4373-82. Crizotinib (PF-02341066) purchased from Selleck.

    (A) VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis. (B) Dose-response curves for both U0126 and axitinib control modulators of EMT. RLU, relative luminescence units.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

  • Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

    Crizotinib impaired tumor vascularization. a-e Representative photomicrographs (40×) of CD31 staining in negative control and indicated LFD, HFD, vehicle (veh) and crizotinib (criz) treated groups. b CD31 was quantified on 5–6 randomly selected regions of n = 2 sections each from each mouse. N = 9–10 mice (a vs b, Veh vs Criz, P = 0.0138)

    Springerplus, 2016, 5:348. Crizotinib (PF-02341066) purchased from Selleck.

  • Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay.

    Int J Proteomics 2011 2011, 215496. Crizotinib (PF-02341066) purchased from Selleck.

    Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated with the indicated inhibitor at 0.1 μM and 1 μM concentrations for two weeks and cell colony size formation was scored under the Nikon inverted-phase microscope.

    Int J Proteomics 2011 2011, Article ID 215496. Crizotinib (PF-02341066) purchased from Selleck.

  • Western blot analysis of c-Met, MAPK and Akt. 0-100nM PF2341066 was added.

     

     

    Dr. Zhang of Tianjin Medical University. Crizotinib (PF-02341066) purchased from Selleck.

产品安全说明书

c-Met抑制剂选择性比较

生物活性

产品描述 Crizotinib (PF-02341066) 克唑替尼是一种有效的c-MetALK抑制剂,在细胞试验中IC50分别为11 nM 和 24 nM。
靶点
c-Met [1]
(A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)
ALK [1]
(Karpas299 cells)
11 nM 24 nM
体外研究

PF-2341066作用于mIMCD3小鼠和MDCK犬上皮细胞,作用于c-Met磷酸化作用时具有相似效果,IC50分别为5 nM 和20 nM。PF-2341066作用于表达c-Met ATP-结合位点突变型V1092I 或H1094R或 P-环突变 M1250T 的NIH3T3 细胞,具有相似的活性,且活力增高,IC50分别为19 nM,2 nM 和15 nM,而作用于表达野生型受体的NIH3T3 细胞时,IC50为13 nM。[1] 相反, 观察到PF-2341066作用于表达c-Met活化环突变型Y1230C 和Y1235D的细胞时,与作用于野生型受体相比,效果发生显著改变,IC50分别为127 nM 和92 nM。PF-2341066 作用于分别表达内源性c-Met 突变体R988C和 T1010I 的NCI-H69 和HOP92 细胞,也有效抑制c-Met 磷酸化, IC50分别为13 nM 和16 nM。与作用于c-Met相比,PF-2341066作用于VEGFR2 和PDGFRβ RTKs, 选择性高1000多倍,作用于IRK和Lck选择性高250多倍,作用于Tie2, TrkA,和TrkB选择性高40到60倍。PF-2341066 作用于RON和 Axl RTKs时选择性为20到30倍。相反,PF-2341066 作用于表达ALK RTK 的核磷蛋白 (NPM)- 间变性淋巴瘤激酶(ALK) 致癌融合突变体和 KARPAS299人间变性大细胞淋巴瘤(ALCL)细胞系时具有相近的IC50值,为24 nM。PF-2341066抑制c-Met依赖的癌细胞的肿瘤表现型,和内皮细胞的血管生成表现型。PF-2341066抑制人GTL-16胃癌细胞生长,IC50为9.7 nM。PF-2341066诱导 GTL-16细胞凋亡,IC50 为8.4 nM。PF-2341066 抑制HGF刺激的人NCI-H441肺癌细胞迁移和入侵,IC50分别为11 nM 和6.1 nM。PF-2341066抑制 MDCK细胞散射,IC50为16 nM。PF-2341066 抑制HGF-刺激的c-Met磷酸化,细胞存活,和Matrigel入侵,IC50分别为11 nM, 14 nM和35 nM。此外, PF-2341066抑制纤维蛋白胶中的血清刺激的 HMVEC分支小管形成 (形成血管)。[1] PF-2341066 作用于Karpas299 或SU-DHL-1 ALCL细胞,也有效抑制 NPM-ALK磷酸化,IC50 为24 nM。PF-2341066 有效抑制细胞增殖,伴随着使细胞周期停在G(1)-S期,且诱导 ALK阳性的 ALCL 细胞凋亡,IC50为30 nM, 但是作用于ALK阴性的淋巴瘤细胞则无效果。 [2] 此外, PF-2341066 抑制骨肉瘤的一些活动行为,及其肿瘤生长 (例如,增殖和存活)和转移 (例如,入侵和形成克隆)。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BAF3 MmP1R5l1d3SxeHnjJGF{e2G7 NVzE[mlNPDhiaB?= M2TTT2ROW09? MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochSUyNIF[xNVc1VCCvdYThcpQh[2:neIDy[ZN{cW6pIFXNUFQhf2m2aDDJR|UxKG:oIECuOlIh|ryP NGH3bGkzOTV5MkW4PS=>
BAF3 MULDfZRwfG:6aXOgRZN{[Xl? MYW0PEBp NWTC[mxVTE2VTx?= MlfER5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKEGOSzDMNVE6Pk1ibYX0ZY51KGOxZYjwdoV{e2mwZzDFUWw1KHerdHigTWM2OCCxZjCyMlIh|ryP MV:yNVU4OjV6OR?=
BAF3 MWXDfZRwfG:6aXOgRZN{[Xl? NVL2bnF1PDhiaB?= MV7EUXNQ MU\DfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochTU2OND3BUGshf2m2aDDJR|UxKG:oIECuNlgh|ryP NIG1ZmkzOTV5MkW4PS=>
Kelly MoT4R5l1d3SxeHnjJGF{e2G7 NVnP[3FOTE2VTx?= MoXtR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT4VtdHliY3XscJMh\XiycnXzd4lv\yCDTFugSlEyPzSOIH31eIFvfCC5aYToJGlEPTBib3[gNE41OiEQvF2= M3uy[lIyPTd{NUi5
SH-SY5Y MUnDfZRwfG:6aXOgRZN{[Xl? M3LvPWROW09? NFSyOW9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUC2VWUXZJINmdGy|IHX4dJJme3OrbnegRWxMKEZzMUe0UEBufXSjboSge4l1cCCLQ{WwJI9nKDBwNUOg{txO MWSyNVU4OjV6OR?=
SMS-KCN NIK4XWVEgXSxdH;4bYMhSXO|YYm= MkXZSG1UVw>? NXHZ[|VpS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW02VLVvDUkBk\WyuczDlfJBz\XO|aX7nJGFNUyCUMUK3OXEhdXW2YX70JJdqfGhiSVO1NEBw\iByLkmxJO69VQ>? MlqzNlE2PzJ3OEm=
BAF3 NEL1[VBEgXSxdH;4bYMhSXO|YYm= MVW0PEBp MoTlSG1UVw>? MlTXR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKFSnbD3BUGshf2m2aDDJR|UxKG:oIECuNVkh|ryP NH\nWIMzOTV5MkW4PS=>
3T3 NVXDRldOTnWwY4Tpc44hSXO|YYm= MYWxJIg> Mm\0SG1UVw>? MXHJcohq[mm2aX;uJI9nKFKRTjDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yODFOwG0> NXHwRoJPOjF6MUK0NVQ>
3T3-E M1PkfGZ2dmO2aX;uJGF{e2G7 NF\hT2YyKGh? MUHEUXNQ NWrwNVU{UW6qaXLpeIlwdiCxZjDUTWUzKGG|c3Xzd4VlKGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkS0PEDPxE1? NUC1UlBZOjF6MUK0NVQ>
A549 M1XE[mtqdmG|ZTDBd5NigQ>? NGG2SXMyKGh? NEe0b4xFVVOR MnzZTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCClLV3FWEBscW6jc3Wg[ZhxemW|c3XkJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gTGdHNWmwZIXj[YQh[XW2b4Doc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4xODhizszN NH60TpQzOThzMkSxOC=>
BAF3-BCL MUjGeY5kfGmxbjDBd5NigQ>? NXfHdZo4OSCq M3zKNmROW09? NInP[WZKdmirYnn0bY9vKG:oIFHCUEBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMT6xOVkh|ryP NX3pbG9COjF6MUK0NVQ>
HEK293 NGrTdZVHfW6ldHnvckBCe3OjeR?= MnjYNUBp MYPEUXNQ M2KwNGlvcGmkaYTpc44hd2ZiQWjMJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkK5OEDPxE1? MYeyNVgyOjRzNB?=
HEK293 MlzHSpVv[3Srb36gRZN{[Xl? M1nNOlEhcA>? M4TGWGROW09? M1jJNWlvcGmkaYTpc44hd2ZiSWKgZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDJwOEi3JO69VQ>? NVTqU|ZQOjF6MUK0NVQ>
Jurkat NXTDeHU3TnWwY4Tpc44hSXO|YYm= NEG0[YIyKGh? M{TSfGROW09? M2LpNGlvcGmkaYTpc44hd2ZiTFPLJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iB{Lke0NUDPxE1? NH7Xd2wzOThzMkSxOC=>
KARPAS299 MlzFT4lv[XOnIFHzd4F6 NV3ybJZiOSCq NUHYcVF3TE2VTx?= M2fJcmlvcGmkaYTpc44hd2ZiQVzLJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCyJO69VQ>? MkLKNlE5OTJ2MUS=
PAE MWrGeY5kfGmxbjDBd5NigQ>? NIHsd5YyKGh? NXy5TppJTE2VTx?= MYnJcohq[mm2aX;uJI9nKFSUS1KgZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwM{m5JO69VQ>? NYrKNWoyOjF6MUK0NVQ>
BAF3 MnfJSpVv[3Srb36gRZN{[Xl? M{\yN|IuOyCm NFPyc3dFVVOR NVP4d|hJUW6qaXLpeIlwdiCxZjDUSWwu\nW|ZXSgbY5{fWyrbjDy[YNmeHSxcjDlfJBz\XO|ZXSge4l1cCCLQ{WwJI9nKDFwNkSzJO69VQ>? Mk\VNlM4PDJ{NUK=
KARPAS299 NEiwbYdEgXSxdH;4bYMhSXO|YYm= MWCyMVMh\A>? MmTJSG1UVw>? NWnLcJRYUUN3ME2wMlA3PDJizszN MnHnNlM4PDJ{NUK=
EBC1 MojwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYS3NkBp M3H2VWROW09? M3LIPGlEPTB;MD6wNlMh|ryP M4W4dVI{QTl|M{K4
HCT116 NXno[FZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVm3NkBp NIn1WFRFVVOR NVTFXnNkUUN3ME2xOE45OiEQvF2= MoTMNlM6QTN|Mki=
MCF7 MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXW3NkBp M4nJU2ROW09? MX;JR|UxRTlwNUig{txO NHnqWFEzOzl7M{OyPC=>
MDA-MB-231 MoXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYf0e5ZlPzJiaB?= NInZd3BFVVOR Ml7sTWM2OD1zMD64JO69VQ>? MmDUNlM6QTN|Mki=
MKN45 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTXSlFZPzJiaB?= MlfuSG1UVw>? NXLYbmZ2UUN3ME2wMlAyOyEQvF2= NWP1XHlMOjN7OUOzNlg>
NCI-H441 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTTO|IhcA>? MonCSG1UVw>? MnrBTWM2OD1zNz6yOUDPxE1? MUKyN|k6OzN{OB?=
NCI-H661 NEi4XoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTQO|IhcA>? NXz3eXQ{TE2VTx?= MYDJR|UxRTFzLkS3JO69VQ>? Mk\qNlM6QTN|Mki=
SK-MEL-28 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\BOVczKGh? M1Pi[WROW09? Mm\FTWM2OD1zMD65O{DPxE1? MYmyN|k6OzN{OB?=
SKOV3 Mmm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorDO|IhcA>? NH7YfpVFVVOR NVW2fW5TUUN3ME2xNk45PSEQvF2= MUWyN|k6OzN{OB?=
SNU5 M1LDW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LISVczKGh? NXW0Zm57TE2VTx?= MkO0TWM2OD1yLkCxOkDPxE1? NVvQfnNVOjN7OUOzNlg>
NCI-H2228 NEnORVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jnXVczKGh? NIjsXIhFVVOR M2\vSWlvcGmkaYTpc44hd2ZiQVzLMYZ2e2mxbjDkdol3\W5iY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjFzODFOwG0> MYOyOFQ{OjlyOR?=
NCI-H3122 NGXRdFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXy3NkBp NHy5OZFFVVOR MnruTY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvOTB6IN88US=> MVmyOFQ{OjlyOR?=
NCI-H3122 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoSwO|IhcA>? Mke0SG1UVw>? M2L4NmlvcGmkaYTpc44hd2ZiQVzLMYZ2e2mxbjDkdol3\W5iY3XscEBxem:uaX\ldoF1cW:wIHnuJIh2dWGwIF7DTU1JOzF{MjDj[YxteyCqYYLic5JqdmdiQVzLJGcyOjZ7QTDteZRidnRid3n0bEBKSzVyIH;mJFAvPjJ|IN88US=> MYmyOFQ{OjlyOR?=
NCI-H3122 NXuzUpIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHzO|IhcA>? MnTmSG1UVw>? MmrpTY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25iaX6gbJVu[W5iTlPJMWg{OTJ{IHPlcIx{KGijcnLvdolv\yCDTFugUFEyQT[PIH31eIFvfCC5aYToJGlEPTBib3[gNE45OzhizszN Mn\YNlQ1OzJ7MEm=
NIH-3T3 MmHtT4lv[XOnIFHzd4F6 MnW0NUBp MYfEUXNQ MU\Jcohq[mm2aX;uJI9nKGi3bXHuJJdqdGRidInw[UBGVUx2LX\1d4VlKEGOSzDlfJBz\XO|ZXSgZZN{\XO|ZXSgZZMheGixc4Doc5J6dGG2ZXSgRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLkC4JO69VQ>? MmLVNlQ1OzJ7MEm=
NIH-3T3 NHG0UWRMcW6jc3WgRZN{[Xl? M33FXVEhcA>? MnjYSG1UVw>? M1mzU2lvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugS|EzPjmDIH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDBwNkC1JO69VQ>? NX3GV451OjR2M{K5NFk>
NIH-3T3 MUDLbY5ie2ViQYPzZZk> MWSxJIg> NFHRVpZFVVOR MmLMTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDTNVIxPllibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOC54Mk[g{txO NGfyTYgzPDR|MkmwPS=>
NIH-3T3 NYPBbI1[U2mwYYPlJGF{e2G7 NXPpfIhYOSCq M1iwNWROW09? MnzDTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDMNVE6Pk1ibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOC56NEOg{txO MorQNlQ1OzJ7MEm=
NIH-3T3 Mo\CT4lv[XOnIFHzd4F6 M3vTNlEhcA>? M3zrZmROW09? MlzkTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDMNVE2OlJibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOS5yMk[g{txO MkHXNlQ1OzJ7MEm=
BAF3 MlPRSpVv[3Srb36gRZN{[Xl? NYK4fZRoPzJiaB?= M1TMV2ROW09? MlPvTY5pcWKrdHnvckBw\iCQUF2vRWxMKHS{YX7z[oVkfGWmIHHzd4V{e2WmIHHzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25id3n0bEBKSzVyIH;mJFAvODVzIN88US=> NWLoUXVzOjR2Nki2N|I>
BAF3 M3fWS2N6fG:2b4jpZ{BCe3OjeR?= M1;0NFczKGh? MoLGSG1UVw>? M2HWNmlEPTB;MD65PEDPxE1? MlW1NlQ1Pjh4M{K=
NIH-3T3 MYfLbY5ie2ViQYPzZZk> MkXGNUBp M2DOZ2lvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugSlEyPzSOIH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDBwMU[1JO69VQ>? MWmyOFgyQTFzNh?=
NIH-3T3 NGPWPY5McW6jc3WgRZN{[Xl? MoPPNUBp MUPJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFOxNVU3YSCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjR5ODFOwG0> M1HabVI1QDF7MUG2
NIH-3T3 NXvxc3JNU2mwYYPlJGF{e2G7 MYCxJIg> M{foZmlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugS|EzODKUIH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDFwMUS4JO69VQ>? NXvsVlVKOjR6MUmxNVY>
NIH-3T3 NYjCUGtSU2mwYYPlJGF{e2G7 NHzNd4gyKGh? NY[5XpNuUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{AyOTVzVHnud{BufXSjboSg[ZhxemW|c3XkJIF{e2W|c3XkJIF{KHCqb4PwbI8uSUyNIHzleoVtKHerdHigTWM2OCCxZjCzMlA{QSEQvF2= MnfxNlQ5OTlzMU[=
KARPAS299 MmHxT4lv[XOnIFHzd4F6 M1\5cFkxKG2rbh?= MYnEUXNQ M3zmW2lvcGmkaYTpc44hd2ZiTmDNMYZ2e2WmIFHMT{BxcG:|cHjvdplt[XSrb36g[ZhxemW|c3XkJJdqfGhiSVO1NEBw\iByLkGxJO69VQ>? NHvPZmwzPDlyMEe1NC=>
MKN 45 M3K0NWtqdmG|ZTDBd5NigQ>? NFLnTGYyKGh? NGTM[W9FVVOR MkL0TY5pcWKrdHnvckBw\iClLV3leEBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEKg{txO M1PPXFI1QTByN{Ww
A549 M3ntbWN6fG:2b4jpZ{BCe3OjeR?= M{DicVQ5KGh? MXTEUXNQ NI[1V|VKSzVyIH;mJFQvODh2IN88US=> NX;lUmFbOjR7MEC4N|A>
NCI-H1975 M{D1ZWN6fG:2b4jpZ{BCe3OjeR?= M{nNZlQ5KGh? NGnBT|lFVVOR M2\zd2lEPTBib3[gO{42PTFizszN MYqyOFkxODh|MB?=
NCI-H1993 M3TTeWN6fG:2b4jpZ{BCe3OjeR?= M3XFWVQ5KGh? MlftSG1UVw>? NWT3XFhXUUN3MDDv[kAxNjB4MTFOwG0> MVqyOFkxODh|MB?=
NCI-H1993 NG\JbXFCeG:2b4Ppd{BCe3OjeR?= NEDSO3IyKM7:TR?= M4\FTlI1KGh? M3vmdWROW09? NWGzZmRM\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppdy=> NIXkdVczPDlyMEizNC=>
NIH-3T3 MkjLR5l1d3SxeHnjJGF{e2G7 NV20dWJqPDhiaB?= NHzLOGdFVVOR MV7JR|UxKG:oIECuN|Y1KM7:TR?= MlzvNlQ6ODB6M{C=
EBC1 NGm2T3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4KxSlczKGh? NYrkdphETE2VTx?= NXjzcZNpUUN3MDDv[kAxNjByNkmg{txO MlPqNlQ6ODB6M{G=
KARPAS299 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHyO|IhcA>? MnzSSG1UVw>? MkCwTWM2OCCxZjCwMlIh|ryP NHjHNVgzPDlyMEizNS=>
NB1 Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXf0NXhCUUN3ME25NU46QCCwTR?= M1vP[nNCVkeHUh?=
NCI-SNU-5 NHT5fWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVS5bFhUUUN3ME2xNFUvPzVibl2= NGfySnBUSU6JRWK=
SR Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HjTGlEPTB;MUK2MlMyKG6P M2j1dnNCVkeHUh?=
SF539 Mln2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4q1W2lEPTB;MkC0MlI1KG6P M{LpfXNCVkeHUh?=
SU-DHL-1 NGm0XXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXmR4ZKSzVyPUOzOk45OiCwTR?= MWnTRW5ITVJ?
SCC-3 MkXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnHTGRMUUN3ME2zOVYvPzZibl2= NGftWVFUSU6JRWK=
DEL MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTN4OT65JI5O M3;WVHNCVkeHUh?=
CTV-1 NYnUfWpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGC0cYJKSzVyPUW5Ok41QCCwTR?= MXfTRW5ITVJ?
EM-2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnNTWM2OD14MEGuN|Qhdk1? MUjTRW5ITVJ?
MHH-CALL-2 MnXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Sx[mlEPTB;NkiyMlU4KG6P MWrTRW5ITVJ?
KM12 M1r5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYe3[JBLUUN3ME23NFYvQSCwTR?= NVrPSIlNW0GQR1XS
KINGS-1 NW\0SXFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PqU2lEPTB;N{S5Mlc2KG6P NWrTRpRrW0GQR1XS
MEG-01 M3TzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTh3Nz62OkBvVQ>? NHLqWZZUSU6JRWK=
BV-173 MlLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDaV4dKSzVyPUGuNFU6QTdizszN NFPj[5RUSU6JRWK=
LAMA-84 NVPP[m82T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DLS2lEPTB;MT6zPFI5OiEQvF2= MVPTRW5ITVJ?
KARPAS-299 NGTm[2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\XSIxDUUN3ME2xMlQxQDZzIN88US=> M{fMd3NCVkeHUh?=
K-562 NYTtelA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4D5RmlEPTB;MT63NlI3QSEQvF2= NWK5Rnl2W0GQR1XS
SK-LMS-1 MlrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEW3cXZKSzVyPUGuO|Y5PjdizszN M3Lhe3NCVkeHUh?=
MOLT-16 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Txb2lEPTB;MT65OVU4PSEQvF2= MYTTRW5ITVJ?
CMK M2O1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XtVGlEPTB;MT65OlE2QSEQvF2= NF;1dHpUSU6JRWK=
ST486 M4DieWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUiwWHZ4UUN3ME2yMlQ{ODd|IN88US=> Mkm4V2FPT0WU
CI-1 NXu4W4FuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjmTWM2OD1{LkS5OlU6KM7:TR?= M2e0N3NCVkeHUh?=
KP-N-RT-BM-1 NFfGS2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmD4TWM2OD1{LkewNVIzKM7:TR?= NVzvVHFFW0GQR1XS
ALL-PO M{j6b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTNwMUiyNFch|ryP M1;lbHNCVkeHUh?=
KS-1 NVn3VHhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYC2c2xEUUN3ME2zMlIyOjJ3IN88US=> MY\TRW5ITVJ?
Becker NXjre4lDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LrXGlEPTB;ND6yN|k{KM7:TR?= NIWzO2xUSU6JRWK=
GDM-1 MoTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLQTWM2OD12LkK0OlE4KM7:TR?= NEXmUFFUSU6JRWK=
BC-1 M1fOUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXGd|NKSzVyPUSuOFkzPzdizszN MV7TRW5ITVJ?
NB14 MnXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTRwOEO1NlQh|ryP M2m3O3NCVkeHUh?=
NOS-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDH[GpKSzVyPUWuN|M5PzRizszN MoPxV2FPT0WU
MZ1-PC MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfGTWM2OD13LkiyNVUyKM7:TR?= MkHVV2FPT0WU
A498 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHDfmdKSzVyPU[uNFg1PzNizszN NI[zUFlUSU6JRWK=
EW-16 MoXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTZwM{e3O|Mh|ryP MmHLV2FPT0WU
NALM-6 NHS2bIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{[1VWlEPTB;Nj62PFM5PyEQvF2= NGWzc25USU6JRWK=
EB-3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXEXYdrUUN3ME23MlA4OjN|IN88US=> NXe0eXBSW0GQR1XS
697 M1HF[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTlwMkSzNlkh|ryP NX7UUG5nW0GQR1XS
Ramos-2G6-4C10 NXnTdGt2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjqenNuUUN3ME25MlU6QDR{IN88US=> MYTTRW5ITVJ?
KNS-81-FD M{\6Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnCTlZKSzVyPUmuOlk3PTNizszN MlXJV2FPT0WU
HUTU-80 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TmeGlEPTB;OT63OFY1OiEQvF2= MYfTRW5ITVJ?
LS-411N NIC2N5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLFcGVKSzVyPUGwMlA2PjdizszN NV65S3JXW0GQR1XS
RPMI-8402 MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTFyLkGxOkDPxE1? MYXTRW5ITVJ?
KU812 Ml7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrITWM2OD1zMD6yPVkyKM7:TR?= NGPt[Y9USU6JRWK=
EW-1 M3XKZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2KxXGlEPTB;MUCuOFQzPSEQvF2= MUjTRW5ITVJ?
HC-1 NVrIW4I6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTFyLkS4OFQh|ryP NEL0SYFUSU6JRWK=
NB69 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTFyLkWwOFMh|ryP NYe4ZZFqW0GQR1XS
MFH-ino MonWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTjTWM2OD1zMD64N|A{KM7:TR?= NVXobmtwW0GQR1XS
CCRF-CEM MkLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Tyb2lEPTB;MUGuOVk4KM7:TR?= NUHSUlBTW0GQR1XS
SK-N-DZ MnzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzvTWM2OD1zMj6wOFM3KM7:TR?= NVXzd3Z5W0GQR1XS
NCI-H720 NEX3XZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TFfWlEPTB;MUKuNVcxPSEQvF2= MlLFV2FPT0WU
HCC1187 M{HtV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\3R|hKSzVyPUGyMlIxPDFizszN NHe5NIZUSU6JRWK=
IST-SL2 MlX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnKXXFKSzVyPUGyMlQ5PzJizszN M4K1UXNCVkeHUh?=
KE-37 MljXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIS5OFJKSzVyPUGyMlc6PjZizszN MkjlV2FPT0WU
HCC1599 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzyOZd4UUN3ME2xNk46ODZ7IN88US=> M3XRcXNCVkeHUh?=
A4-Fuk NIfXdldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTF{Lkm1PFYh|ryP NEnlRpZUSU6JRWK=
NKM-1 NUH4bXh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{i4NmlEPTB;MUOuNlkzPSEQvF2= NULmWYNoW0GQR1XS
BE-13 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\hUGlEPTB;MUOuO|k5QSEQvF2= M4[5bHNCVkeHUh?=
MV-4-11 NXvWZodWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjHZpMzUUN3ME2xOE4xOzJ2IN88US=> NI\1W5FUSU6JRWK=
OPM-2 M{HRZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LhSGlEPTB;MUSuOFA5PSEQvF2= NYnsT2djW0GQR1XS
KARPAS-422 MontS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfkTWM2OD1zND61NVI3KM7:TR?= M4rQ[3NCVkeHUh?=
RPMI-8226 NH3UcpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEezcolKSzVyPUG0Mlg6OTVizszN MVTTRW5ITVJ?
KARPAS-45 MmOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\rNnpKSzVyPUG1Mlc4OTZizszN NV2y[GxSW0GQR1XS
SK-PN-DW MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moq2TWM2OD1zNT64OlMyKM7:TR?= Ml\yV2FPT0WU
LC-2 M{fmfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHWTWM2OD1zNj6xOVA3KM7:TR?= M4\DbXNCVkeHUh?=
NCI-H1648 NFvzSZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInnSndKSzVyPUG2MlI2PCEQvF2= MnHVV2FPT0WU
RL95-2 M3T2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DUOGlEPTB;MU[uN|k4QCEQvF2= NGXEXpdUSU6JRWK=
KNS-42 NXnqRYdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3TXohKSzVyPUG2MlczPzRizszN MlfYV2FPT0WU
RPMI-6666 NETOfWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILnWJZKSzVyPUG2MlkzOTFizszN MXzTRW5ITVJ?
SIG-M5 NHL5TW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTF5LkG5NFMh|ryP M3LwR3NCVkeHUh?=
VA-ES-BJ MkHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrsT|lKSzVyPUG3Mlc1PTFizszN MmrDV2FPT0WU
MONO-MAC-6 NVHsSZNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPaTWM2OD1zNz65N|EzKM7:TR?= MVTTRW5ITVJ?
LAN-6 NXHtRpl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fGPWlEPTB;MUiuO|U2PyEQvF2= M1nZXnNCVkeHUh?=
A388 Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHpNWNLUUN3ME2xPU4{ODV7IN88US=> MkC2V2FPT0WU
SK-NEP-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPnTWM2OD1{MD6yNVMzKM7:TR?= M2HHNXNCVkeHUh?=
TE-10 Mnv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTwNG1KSzVyPUKwMlUzOjFizszN MUfTRW5ITVJ?
HL-60 M3XyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\H[mQ5UUN3ME2yNE46ODl7IN88US=> NIfiN2NUSU6JRWK=
MC116 Mm\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TYbGlEPTB;MkGuO|IzOSEQvF2= NYizTJhUW0GQR1XS
SW962 NFPY[IRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHMbJVKSzVyPUKxMlc6OTVizszN NUPEbIlEW0GQR1XS
NOMO-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTJ{Lk[1OlQh|ryP NWW5XnJQW0GQR1XS
CTB-1 NX\XTHZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrNOGdKSzVyPUKyMlg3PzFizszN NV\jeJg{W0GQR1XS
MRK-nu-1 MonLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlL2TWM2OD1{Mj65NFc1KM7:TR?= MUTTRW5ITVJ?
GR-ST M2THOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXn3WodqUUN3ME2yN{44PiEQvF2= M1;OfnNCVkeHUh?=
HH NHzLWJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXz3RWE5UUN3ME2yOE4xODNizszN NFnGbIRUSU6JRWK=
NCI-H1963 NUnTTmE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfGTWM2OD1{ND6wO|gzKM7:TR?= MmTTV2FPT0WU
QIMR-WIL M{G0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfnTXNKSzVyPUK0Mlg4PzJizszN M3\3VXNCVkeHUh?=
CGTH-W-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTJ3LkC3NlMh|ryP NYnnN443W0GQR1XS
LP-1 NEm3SZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;hTWM2OD1{NT62OVUyKM7:TR?= NFXiVoxUSU6JRWK=
NCI-H748 NET2T3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\zcmlEPTB;Mk[uOVE{PyEQvF2= MmrRV2FPT0WU
PF-382 M3\Xb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTJ5LkKyNlMh|ryP M4rHNXNCVkeHUh?=
ATN-1 NGP6bGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInlOXhKSzVyPUK3MlM4OzJizszN MVLTRW5ITVJ?
L-540 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTPeYt2UUN3ME2yO{43PDV7IN88US=> M37SfnNCVkeHUh?=
LXF-289 M1nD[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rnVGlEPTB;MkeuO|UyQSEQvF2= NGfaUIxUSU6JRWK=
LS-513 NXXoZ|NUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJ6LkG4NFch|ryP M3fMfHNCVkeHUh?=
NCI-H1581 M{f6Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknmTWM2OD1|MD6zPVc3KM7:TR?= MV;TRW5ITVJ?
ES6 MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTNyLk[4PVkh|ryP NHHUboxUSU6JRWK=
SW982 M2G5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7xdWNKSzVyPUOwMlg2PjZizszN NHzwUWhUSU6JRWK=
DOHH-2 NUP0doI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWL0TGliUUN3ME2zNU42QDl|IN88US=> MYfTRW5ITVJ?
DB NFjRNoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWP1OIFKUUN3ME2zN{46PDNzIN88US=> MYDTRW5ITVJ?
MPP-89 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTN2LkG3OVYh|ryP MVPTRW5ITVJ?
LB831-BLC MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvNTWM2OD1|ND61NVg1KM7:TR?= M2TTeHNCVkeHUh?=
NB5 NEmxboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXk[XNKSzVyPUO0Mlg2OzVizszN NHewUWZUSU6JRWK=
GB-1 M4jjeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkG2TWM2OD1|NT6wOFY6KM7:TR?= NIPTUpRUSU6JRWK=
TE-15 NEP5S4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\HbW9KSzVyPUO1MlIzOzhizszN M324UnNCVkeHUh?=
LC4-1 M3nlUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPDTWM2OD1|NT6zPFQ4KM7:TR?= MWrTRW5ITVJ?
NCI-H747 NV;CNFFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DQdmlEPTB;M{[uNVM3QSEQvF2= NVq3dY1uW0GQR1XS
NTERA-S-cl-D1 NYHYXoFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mme3TWM2OD1|OD63N|Q4KM7:TR?= M1PIT3NCVkeHUh?=
SK-MM-2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfaTWM2OD12MD6xNVQ3KM7:TR?= MXrTRW5ITVJ?
TGW NF\IO2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTRzLkC1OlMh|ryP NVKzT5Y{W0GQR1XS
ONS-76 NHPJ[45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTR{LkS4PFMh|ryP M4i5bnNCVkeHUh?=
CPC-N NUW4To14T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGq4R49KSzVyPUSyMlk6PzFizszN MX;TRW5ITVJ?
ES4 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\Y[2lEPTB;NESuOFE2OyEQvF2= MnLXV2FPT0WU
Daudi NVPiT2JZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\3TWM2OD12NT6wPFI4KM7:TR?= M1TiS3NCVkeHUh?=
MOLT-4 MkjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\Me2lEPTB;NEWuNFg2OyEQvF2= M17M[HNCVkeHUh?=
HT-144 Mnf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHL4OHBKSzVyPUS2MlczPiEQvF2= MULTRW5ITVJ?
SW872 NVz5UnVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4qye2lEPTB;NEiuNVk{OyEQvF2= MkO4V2FPT0WU
D-283MED NVeydZJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7C[VhyUUN3ME20PE4{PTR{IN88US=> NUXIUoVnW0GQR1XS
NCI-H2126 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIP2NlRKSzVyPUS4Mlg1PzZizszN MVPTRW5ITVJ?
NCI-SNU-16 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDXTWM2OD12OT6yNVQ{KM7:TR?= MVXTRW5ITVJ?
CESS NXm3fGFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV25PGRVUUN3ME20PU42ODh6IN88US=> NEjvXGVUSU6JRWK=
A101D Mn;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTR7Lkm3N|Yh|ryP NXHtNnRjW0GQR1XS

... Click to View More Cell Line Experimental Data

体内研究 PF-2341066每天按50 mg/kg和75 mg/kg剂量处理GTL-16 模型, 引起大肿瘤 (体积大于600 mm3) 明显衰退,且按43天处理日程处理后,平均肿瘤体积降低60%。在另一项研究中, PF-2341066处理3个月以上,完全抑制GTL-16肿瘤生长,PF-2341066每天按50 mg/kg剂量处理小鼠,3个月后,只有1/12小鼠的肿瘤生长得到提高。PF-2341066每天按50 mg/kg剂量处理NCI-H441 NSCLC 模型处理周期为38天,观察到平均肿瘤体积降低43%。PF-2341066 每天按50 mg/kg剂量作用于 Caki-1 RCC模型,处理周期为33天,观察到平均肿瘤体积降低53%,且每种肿瘤体积降低至少30%。PF-2341066每天按 50 mg/kg剂量作用于 U87MG 恶性胶质瘤或PC-3前列腺癌移植瘤模型,几乎完全抑制肿瘤生长,在实验最后一天,抑制分别达97% 或84%。相反, PF-2341066每天按50 mg/kg剂量口服给药处理 MDA-MB-231 乳腺癌模型,或 DLD-1 结肠癌模型,不会显著抑制肿瘤生长。PF-2341066每天按12.5 mg/kg, 25 mg/kg, 和50 mg/kg剂量作用于 GTL-16 肿瘤,观察到CD31阳性内皮细胞显著降低,这种作用存在剂量依赖性,说明 MVD 受抑制,且具有相关的抗癌高效性,这种作用也存在剂量依赖性。PF-2341066 作用于GTL-16 和 U87MG 模型,显著降低人VEGFA 和IL-8血浆水平,这种作用存在剂量依赖性。PF-2341066口服处理GTL-16 肿瘤,观察到磷酸化的c-Met, Akt, Erk, PLCλ1,和 STAT5水平显著受抑制。[1]PF-2341066 每天按100 mg/kg剂量口服处理携带Karpas299 ALCL 移植瘤的SCID Beige 小鼠,具有抗癌高效性,这种作用存在剂量依赖性,处理15天,所有肿瘤完全衰退。此外, PF-2341066抑制关键NPM-ALK信号调节器, 包括磷脂酶C-γ, 信号转导器,及转录因子3, 细胞外信号调节激酶, 和Akt的激活剂,这些与 NPM-ALK 磷酸化和功能受抑制相关。[2] PF-2341066 抑制骨肉瘤的一些活动行为,及其肿瘤生长(例如, 增殖和存活)和转移 (例如,入侵和形成克隆)。PF-2341066口服饲喂裸鼠,抑制生长和相关的骨肉瘤裸鼠移植瘤的骨基质的形成。[3] PF-2341066 按50 mg/kg 剂量处理 c-MET-扩增的GTL-16移植瘤,引起肿瘤衰退,这与18F-FDG 摄取的缓慢降低相关,且降低葡糖糖转运蛋白 1, GLUT-1的表达。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

生化激酶实验:

使用连续耦合的分光光度测定c-Met催化活性,通过分析NADH消耗率而测定c-Met诱导的ADP产量,这种作用具有时间依赖性。在 340 nm处使用分光光度法在指定时间点测定吸光值的降低而计算NADH的消耗量。为了测定Ki值, 在含实验试剂的实验孔中加入不同浓度PF-2341066,然后在37oC下温育10分钟。加入c-Met酶开始进行实验反应。
细胞实验:

[1]

+ 展开
  • Cell lines: GTL-16胃癌细胞和T47D乳腺癌细胞
  • Concentrations: 0 nM-256 nM
  • Incubation Time: 1小时
  • Method:

    GTL-16胃癌细胞和T47D乳腺癌细胞接种在96孔板上,孔中含培养基,培养基中含10% 胎牛血清(FBS),然后转移到无血清培养基中[含0.04%牛血清蛋白(BSA)],处理 24小时。 在调查配体依赖的RTK 磷酸化实验中,加入相应的生长因子,处理20分钟。细胞和 PF-2341066和/或适当配体在指定时间温育1小时,然后使用含 1 mmol/L Na3VO4的HBSS冲洗细胞一次,然后从细胞中获得蛋白裂解物。随后,通过夹心酶联免疫吸附试验法使用特定的捕获抗体在96孔板上测定选定蛋白激酶的磷酸化,使用特点检测抗体测定磷酸化的酪氨酸残基。抗体包被的实验板(a) 在蛋白裂解物存在时,在4oC下过夜;(b)在溶于PBS的1% Tween-20 中冲洗7次;(c)在辣根过氧化物酶标记的抗总磷酸(PY-20)抗体(1:500)中温育20分钟;(d) 再次冲洗7次;(e)在3,3,5,5-四甲基联苯胺过氧化物酶底物中温育,开始显示反应,加入0.09 N H2SO4终止反应; (f)在450 nm 处使用分光光度计测定吸光度。


    (Only for Reference)
动物实验:

[1]

+ 展开
  • Animal Models: 携带NCI-H441,或DLD-1,或MDA-MB-231的雌性和雄性nu/nu小鼠
  • Formulation: --
  • Dosages: 12.5 mg/kg/day, 25 mg/kg/day, 和50 mg/kg/day
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 9 mg/mL (19.98 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+dd H2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 450.34
化学式

C21H22Cl2FN5O

CAS号 877399-52-5
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03737994 Not yet recruiting ALK Gene Rearrangement|ALK Positive|Lung Non-Squamous Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8 National Cancer Institute (NCI) April 1 2019 Phase 2
NCT03737994 Not yet recruiting ALK Gene Rearrangement|ALK Positive|Lung Non-Squamous Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8 National Cancer Institute (NCI) April 1 2019 Phase 2
NCT03874273 Recruiting Inflammatory Myofibroblastic Tumor Federal Research Institute of Pediatric Hematology Oncology and Immunology February 1 2019 Phase 2|Phase 3
NCT03874273 Recruiting Inflammatory Myofibroblastic Tumor Federal Research Institute of Pediatric Hematology Oncology and Immunology February 1 2019 Phase 2|Phase 3
NCT03672643 Recruiting ALK-positive NSCLC Pfizer January 28 2019 Phase 4
NCT03672643 Recruiting ALK-positive NSCLC Pfizer January 28 2019 Phase 4

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?

  • 回答:

    Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

相关c-Met产品

Tags: 购买Crizotinib (PF-02341066) | Crizotinib (PF-02341066)供应商 | 采购Crizotinib (PF-02341066) | Crizotinib (PF-02341066)价格 | Crizotinib (PF-02341066)生产 | 订购Crizotinib (PF-02341066) | Crizotinib (PF-02341066)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID